Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Trial Details

NCT ID
NCT06080061
Phase
PHASE1
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Hypofractionated accelerated radiation therapy
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302
  • San Jose, California, United States|37.33939,-121.89496

Key Eligibility Criteria

  • Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for defini…
  • ECOG performance status of 0-2
  • Age ≥ 18 years old
  • Ability to understand and the willingness to personally sign the written IRB approved informed consent document

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →